Kiliç Zuhal, Isgör Yasemin G, Olgen Süreyya
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ankara, Tandogan-Ankara, Turkey.
Arch Pharm (Weinheim). 2009 Jun;342(6):333-43. doi: 10.1002/ardp.200800216.
A series of novel 1,3,5-trisubstituted indole derivatives, namely, N-benzyl 5-phenyl indole-3-imine, N-benzyl-5-(p-fluorophenyl)indole-3-imine and their corresponding amine congeners, were designed and synthesized as pp60(c-Src) tyrosine kinase inhibitors, and their inhibitory activities toward pp60(c-Src) tyrosine kinase were evaluated by in-vitro kinase assay. Pre-screening at two doses of compounds against kinase target revealed that, except for the N-benzyl-5-phenyl indole imine derivatives 7a-7d, all indole derivatives show the target inhibition at varying levels. Consequently, the compounds, 8c, 8f, 8g, and 8h, were selected for prescreening tests. The dose-response curves for up to six concentrations (250 to 7.8 muM) of the active compounds were obtained by tyrosine kinase assay and the four-parameter logistic analysis of these data resulted in the IC(50)s of 4.69, 74.79, 75.06, and 84.23 muM for compounds 8c, 8f, 8g, and 8h, respectively. Therefore, compound 8c, 1-(1-benzyl-5-phenyl-1H-indole-3-yl)-N-(4-fluorobenzyl)methanamine.HCl, was the promising inhibitor for pp60(c-Src), followed by compounds 8g and 8h. Under the same conditions, compound 8f did not provide any reasonable inhibition pattern to be considered as active compound. Therefore, among all four active compounds, compound 8f was not found suitable for further analysis.
设计并合成了一系列新型的1,3,5-三取代吲哚衍生物,即N-苄基-5-苯基吲哚-3-亚胺、N-苄基-5-(对氟苯基)吲哚-3-亚胺及其相应的胺类同系物,作为pp60(c-Src)酪氨酸激酶抑制剂,并通过体外激酶测定评估了它们对pp60(c-Src)酪氨酸激酶的抑制活性。以两种剂量的化合物针对激酶靶点进行预筛选,结果显示,除了N-苄基-5-苯基吲哚亚胺衍生物7a-7d外,所有吲哚衍生物均表现出不同程度的靶点抑制作用。因此,选择化合物8c、8f、8g和8h进行预筛选测试。通过酪氨酸激酶测定获得了活性化合物高达六个浓度(250至7.8 μM)的剂量-反应曲线,对这些数据进行四参数逻辑分析得出,化合物8c、8f、8g和8h的IC50分别为4.69、74.79、75.06和84.23 μM。因此,化合物8c,即1-(1-苄基-5-苯基-1H-吲哚-3-基)-N-(4-氟苄基)甲胺·盐酸盐,是pp60(c-Src)的有前景的抑制剂,其次是化合物8g和8h。在相同条件下,化合物8f未呈现任何合理的抑制模式,不能被视为活性化合物。因此,在所有四种活性化合物中,化合物8f不适合进一步分析。